Evidence map›Paper›PMID 27822364›Full record

ArticleRSC advances2016

New withanolides with TRAIL-sensitizing effect from

Li-Xia Chen, Gui-Yang Xia, Hao He, Jian Huang, Feng Qiu, Xiao-Lin Zi

Open access · greenAbstract read
In one paragraph

Article in RSC advances, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
7.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. New withanolides fromRSC advances · 2020
    Article
  5. Cytotoxic Withanolides from the Whole Herb ofMolecules (Basel, Switzerland) · 2019
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Li-Xia ChenDepartment of Natural Products Chemistry, School of Traditional Chinese Materia Medica, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China; Department of Urology, University of California, Irvine, Orange, CA 92868, USA.
Gui-Yang XiaDepartment of Natural Products Chemistry, School of Traditional Chinese Materia Medica, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China; School of Chinese Materia Medica and Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, People's Republic of China.
Hao HeSchool of Pharmaceutical Sciences, Xi' an Medical University, Xi' an 710021, People's Republic of China.
Jian HuangDepartment of Natural Products Chemistry, School of Traditional Chinese Materia Medica, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China.
Feng QiuDepartment of Natural Products Chemistry, School of Traditional Chinese Materia Medica, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China; School of Chinese Materia Medica and Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, People's Republic of China.
Xiao-Lin ZiDepartment of Urology, University of California, Irvine, Orange, CA 92868, USA.
Shenyang Pharmaceutical University · CNOrange (Poland) · PLUniversity of California, Irvine · USXi'an Medical University · CN

Funding

The NEDD8 pathway mediated Skp2 degradation in chemoprevention by FKAR01CA193967 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI ZI, XIAOLIN · 2016 to 2020
$1.8M
Chemoprevention of urinary bladder carcinogenesis by flavokawain AR01CA122558 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI ZI, XIAOLIN · 2008 to 2012
$1.7M
Rhodiola Rosea Extracts, Salidroside and Bladder Cancer ChemopreventionR21CA152804 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI ZI, XIAOLIN · 2011 to 2012
$366k
NCI NIH HHS R01 CA122558NCI NIH HHS R01 CA193967NCI NIH HHS R21 CA152804
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID27822364
PMCPMC5095689
OpenAlexW2399715908

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.